The heart metabolism: Pathophysiological aspects in ischaemia and heart failure

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 827-835

  Abozguia, K ^a   Shivu, G Nallur ^a   Ahmed, I ^a   Phan, T T ^a   Frenneaux, M P ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Heart failure; Ischaemia; Myocardial metabolism; Pathophysiology

Indexed keywords

ACIPIMOX; CREATINE; CREATINE KINASE; CREATINE PHOSPHATE; FATTY ACID; PERHEXILINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; TRIMETAZIDINE;

CITRIC ACID CYCLE; DISEASE COURSE; ENERGY TRANSFER; FAT INTAKE; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE METABOLISM; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MYOCARDIAL HIBERNATION; NONHUMAN; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STUNNED HEART MUSCLE;

ADENOSINE TRIPHOSPHATE; CARNITINE O-PALMITOYLTRANSFERASE; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXYGEN CONSUMPTION; VASODILATOR AGENTS;

EID: 65649135100     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582101     Document Type: Review

References (100)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - A growing challenge. N Eng J Med 2007; 356: 213.
2. Allender S, Peto V, Scarborough P, Kaur A, Rayner M. Coronary Heart Disease Statistics. London: British Heart Foundation 2008.
3. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC, Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
4. Gibbs JSR, McCoy ASM, Gibbs LME, Rogers AE, Addington-Hall JM. Living with and dying from heart failure: The role of palliative care. Heart 2002; 88(Suppl 2): Ii36-9.
5. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet 2003; 361: 847-58.
6. Tendera M. Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. Eur Heart J Suppl 2005; 7: 5-9.
7. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV. More æmalignantÆhan cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-22.
8. Mcmurray J, Mcdonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14: 1158-62.
9. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005) The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26(11), 1115-40. Eur Soc Cardiology.
10. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Blockade after myocardial infarction: Systematic review and meta regression analysis. Br Med J 1999; 318: 1730-7.
11. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.
12. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 2006; 3: 490-8.
13. Abozguia K, Nallur Shivu G, Phan TT, Ahmed I, Maher AR, Frenneaux M. Potential of metabolic agents as adjunct therapies in heart failure. Future Cardiol 2007; 3: 525-35.
14. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: Potential for therapeutic interventions. Heart Fail Rev 2002; 7: 115-30.
15. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34: 25.
16. Mallet RT, Sun J, Knott EM, Sharma AB, Olivencia-Yurvati AH. Metabolic cardioprotection by pyruvate: Recent progress. Experiment Biol Med 2005; 230(7): 435-43. SEBM.
17. Depre C, Vanoverschelde JLJ, Taegtmeyer H. Glucose for the heart circulation. Am Heart Assoc 1999; 99(4): 578-88.
18. Opie LH. Hypothesis: Glycolytic rates control cell viability in ischemia. J Appl Cardiol 1988; 3: 407-14.
19. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiolog Rev 2005; 85: 1093-129.
20. Fell DA, Thomas S. Increasing the flux in metabolic pathways: A metabolic control analysis perspective. Biotechnol Bioeng 1998; 58: 121-4.
21. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Investig 1988; 82: 2017.
22. Kemppainen J, Fujimoto T, Kalliokoski KK, Viljanen T, Nuutila P, Knuuti J. Myocardial and skeletal muscle glucose uptake during exercise in humans. J Physiol 2002; 542: 403-12.
23. How OJ, Aasum E, Kunnathu S, Severson DL, Myhre ESP, Larsen TS. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol- Heart Circ Physiol 2005; 288: 2979-85.
24. Kjekshus JK, Mjos OD. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest 1972; 51: 1767-76.
25. Mjos OD, Kjekshus JK, Lekven J. Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J Clin Investig 1974; 53: 1290.
26. Hutter JF, Piper HM, Spieckerman PG. Effect of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol 1985; 249: 723-8.
27. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am J Physiol Heart Circ Physiol 2001; 280: H977-83.
28. Schrauwen P, Hoeks J, Schaart G, Kornips E, Binas B, Van De Vusse GJ, et al. Uncoupling protein 3 as a mitochondrial fatty acid anion exporter. FASEB J 2003; 17: 2272-4.
29. Goglia F, Skulachev VP. A function for novel uncoupling proteins: antioxidant defense of mitochondrial matrix by translocating fatty acid peroxides from the inner to the outer membrane leaflet. FASEB J 2003; 17(12): 1585-91.
30. Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K. Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am J Physiol Heart Circ Physiol 2001; 280: H977-83.
31. Lommi J, Kupari M, Yki-J-Rvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 1998; 81: 45-50
32. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004; 364: 1786-8.
33. Kjekshus JK, Mjos OD. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest 1972; 51: 1767-76.
34. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 1971; 50: 1386-9.
35. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med 1954; 16: 504-15.
36. Kjekshus JK, Mjos OD. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest 1972; 51: 1767-76.
37. King LM, Opie LH. Glucose and glycogen utilisation in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol Cell Biochem 1998; 180: 3-26.
38. Lerch R, Tamm C, Papageorgiou I, Benzi RH. Myocardial fatty acid oxidation during ischemia and reperfusion. Mol Cell Biochem 1992; 116: 103-9.
39. Lopaschuk GD, Spafford MA, Davies NJ, Wall SR. Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res 1990; 66: 546-53.
40. Kantor PF, Dyck JRB, Lopaschuk GD. Fatty acid oxidation in the reperfused ischemic heart. Am J Med Sci 1999; 318: 3.
41. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Experiment Therapeut 1993; 264: 135-44.
42. Heusch G. Hibernating myocardium. Physiolog Rev 1998; 78: 1055-85.
43. Kennedy JA, Kiosoglous AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2003; 6: 794.
44. Murnaghan MF. Effect of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit. Br J Pharmacol 1981; 73: 909.
45. Vanoverschelde JL, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M, et al. Mechanisms of chronic regional post-ischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993; 87: 1513-23.
46. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol- Heart Circ Physiol 2003; 285: 579-88.
47. McNulty PH, Jagasia D, Cline GW, Ng CK, Whiting JM, Garg P, et al. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation 2000; 101(8): 917-22.
48. Gerber BL, Wijns W, Vanoverschelde JLJ, Heyndrickx GR, De Bruyne B, Bartunek J, et al. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina Direct evidence for myocardial stunning in humans. J Am College Cardiol 1999; 34: 1939-46.
49. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction an overview of randomized placebo-controlled trials. Circulation 1997; 96: 1152-6.
50. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: A report from the DIGAMI 2 trial. Eur Heart J 2008; 29: 166-76.
51. Schwaiger M, Schelbert HR, Ellison D, Hansen H, Yeatman L, Vinten-Johansen J, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am College Cardiol 1985; 6: 336-47.
52. Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989; 64: 860-5.
53. Janier MF, Vanoverschelde JL, Bergmann SR. Ischemic preconditioning stimulates anaerobic glycolysis in the isolated rabbit heart. Am J Physiol- Heart Circ Physiol 1994; 267: 1353-60.
54. Shimonagata T, Nanto S, Kusuoka H, Ohara T, Inoue K, Yamada S, et al. Metabolic changes in hibernating myocardium after percutaneous transluminal coronary angioplasty and the relation between recovery in left ventricular function and free fatty acid metabolism. Am J Cardiol 1998; 82: 559-63.
55. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure a randomized, controlled trial of short-term use of a novel treatment, circulation Am Heart Assoc 2005; 112(21): 3280-8.
56. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16.
57. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25(20): 1814-21.
58. Bonnet D, Martin D, de Lonlay P, Villain E, Jouvet P, Rabier D, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. circulation. Am Heart Assoc 1999; 100(22): 2248-53
59. Mathur A, Sims HF, Gopalakrishnan D, Gibson B, Rinaldo P, Vockley J, et al. Molecular heterogeneity in very-long-chain acylcoa dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 1999; 99(10): 1337-43.
60. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998; 83(10): 969-79.
61. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, et al. Moderate severity heart failure does not involve a down-regulation of myocardial fatty acid oxidation. Am J Physiol- Heart Circ Physiol 2004; 287: 1538-43.
62. Tian R, Musi N, D'Agostino J, Hirshman MF, Goodyear LJ. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 2001; 104(14): 1664-9.
63. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000; 10: 1247-55.
64. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F] fluoro-6-thia-heptadecanoic acid and [18F] FDG in Patients with Congestive Heart Failure. J Nucl Med 2001; 42: 55-62.
65. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 2004; 61: 297-306.
66. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991; 40: 972-7.
67. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91(2): 161-5.
68. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006; 114: 2130.
69. Shen W, Asai K, Uechi M, Mathier MA, Shannon RP, Vatner SF, et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: A compensatory role for the parallel loss of creatine. Circulation 1999; 100: 2113-8.
70. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 1996; 78: 893-902
71. Shen W, Asai K, Uechi M, Mathier MA, Shannon RP, Vatner SF, et al Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: A compensatory role for the parallel loss of creatine. Circulation 1999; 100: 2113-8.
72. Neubauer S, Remkes H, Spindler M, Horn M, Wiesmann F, Prestle J, et al. Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 1999; 100: 1847-50.
73. Tian R, Ingwall JS. The molecular energetics of the failing heart from animal modelssmall animal models. Heart Fail Rev 1999; 4: 245-53.
74. Zhang J, Bache R. The molecular energetics of the failing heart from animal models - large animal models. Heart Fail Rev 1999; 4: 255-67
75. Nakae I, Mitsunami K, Omura T, Yabe T, Tsutamoto T, Matsuo S, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 2003; 42: 1587-93.
76. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991; 122: 795-801.
77. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991; 338: 973-6.
78. Hansch A, Rzanny R, Heyne JP, Leder U, Reichenbach JR, Kaiser WA, Noninvasive measurements of cardiac high-energy phosphate metabolites in dilated cardiomyopathy by using 31P spectroscopic chemical shift imaging. Eur Radiol 2005; 15: 319-23.
79. Murray AJ, Lygate CA, Cole MA, Neubauer S, Clarke K. Insulin resistance, abnormal energy metabolism and increased inschaemic damage in the chronically infracted rat heart. Cardiovasc J S Afr 2004; 15: S14.
80. Scheuermann-Freestone M, Neubauer S, Clarke K. Abnormal cardiac muscle function in heart failure is related to insulin resistance. Cardiovasc J S Afr 2004; 15: S12.
81. Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 1995; 92: 15-23.
82. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998; 97: 2536-42.
83. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-6.
84. Neubauer S, Remkes H, Spindler M, Horn M, Wiesmann F, Prestle J, et al. Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 1999; 100: 1847-50.
85. De Sousa E, Veksler V, Minajeva A, Kaasik A, Mateo P, Mayoux E, et al. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res 1999; 85: 68-76.
86. Gross WL, Bak MI, Ingwall JS, Arstall MA, Smith TW, Balligand JL, et al. Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Proc Natl Acad Sci USA 1996; 93: 5604-9.
87. Gordon A, Hultman E, Kaijser L, Kristjansson S, Rolf CJ, Nyquist O, et al. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 1995; 30: 413-8.
88. Andrews R, Greenhaff P, Curtis S, Perry A, Cowley AJ. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 1998; 19: 617-22.
89. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and hosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27(8): 942-8.
90. Horowitz JD, Mashford ML. Perhexiline maleate in the treatment of severe angina pectoris. Med J Aust 1979; 1: 485-8.
91. Wallace DC. Perhexiline maleate in the treatment of angina pectoris. Five years of personal Clin experience. Med J Aust 1978; 2: 466, 493-66, 495.
92. White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients refractory to beta-adrenoreceptor blockade. Int J Cardiol 1983; 3: 145-55.
93. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, et al. Efficacy and safety of perhexiline maleate in re fractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
94. Horgan JH, O'Callaghan WG, Teo KK. Therapy of angina pectoris with low-dose perhexiline. J Cardiovasc Pharmacol 1981; 3: 566-72.
95. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52: 273-80.
96. Opie L. The Heart: Physiology from cell to circulation. Philadelphia: Lippincourt-Raven 1998.
97. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid fractory angina. A double-blind placebo-controlled clinical trial of oxidation to glucose oxidation by inhibiting mitochondrial longchain 3-ketoacyl coenzyme a thiolase. Circ Res 2000; 86(5): 580-8.
98. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion injury: The search for therapeutic targets. Curr Pharm Des 2008; 14(12): 1205-16.
99. Mongiovi M, Pipitone S. Supraventricular tachycardia in fetus: How can we treat? Curr Pharm Des 2008; 14(8): 736-42.
100. Origasa H, Goto S, Uchiyama S, Shimada K, Ikeda Y. The Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Events (J-TRACE): A nation-wide, prospective large cohort study; the study design. Circ J 2008; 72(6): 991-7.